eMedevents
  • 143,382+ Medical Conferences
  • 279 Specialties
  • 10,799 Organizers
  • 154,015 Speakers
  • 156 Countries
  • 4,642 Cities
47,794+
CME Conference Registrations Sold
Home  >  Speakers  >  Matthias G. Von Herrath
Matthias G. Von Herrath

Matthias G. Von Herrath

    MD, PhD
Vice President, Director, Professor | La Jolla, California    United States of America
Immunology And Microbiology
Clinical Endpoints In T1D Trials: What Can We Do Immunology And Microbiology,...More
Spoken at 8 events
Speaking at 1 event

Biography :

Dr. von Herrath is Professor/Member with Tenure at the La Jolla Institute for Allergy and Immunology, United States since last June. He received his M.D. in 1998 from the Freiburg Medical School, Germany. The focus of Dr. von Herrath’s research is to devise novel strategies to prevent type 1 diabetes by inducing autoreactive regulatory T cells. Furthermore, positive as well as negative associations between viral infections and autoimmune disease are being investigated. He is member of the FOCIS Steering Committee, International Diabetes Society Council, Clinical Immunology Society Council and Section Editor for JI Cutting Edge as well as Clinical Immunology.

Matthias von Herrath, M.D., and his team study why the immune system sometimes attacks the body's own cells. They focus on type 1 diabetes, a disease caused by the immune system attacking the insulin-producing beta cells in the pancreas, and on diseases caused by viral infections. Their goal is to develop and evaluate new treatments and therapies for these conditions, in particular immune-based interventions.

The laboratory has found that stimulating the immune system with beta cell proteins via DNA vaccines results in a beneficial, or regulatory, immune response that can prevent type 1 diabetes. The DNA vaccines are currently being developed for the clinic in collaboration with BayHill therapeutics.

*****************
************
 
For speaker's contact information - Contact us

Specialties

Immunology and Microbiology

Interested Topics

Clinical Endpoints in T1D Trials: What can we do Better?, Immunology and Microbiology, Diabetes, Molecular Biology, Cell Culture, Infectious Diseases, Biochemistry, Clinical Trials, Protein Chemistry, Virology, Immunohistochemistry, Clinical Research

State Licenses

This section has yet to be updated by the speaker.

Board Certifications

This section has yet to be updated by the speaker.

Professional Association

This section has yet to be updated by the speaker.

Languages

English

Conference Session Materials

Close

Send Message